<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2401">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590261</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201138</org_study_id>
    <secondary_id>2020-A02700-39</secondary_id>
    <nct_id>NCT04590261</nct_id>
  </id_info>
  <brief_title>Myeloid Cells in Patients With Covid-19 Pneumonia</brief_title>
  <acronym>MyeloidCovid</acronym>
  <official_title>Myeloid Cells in Patients With Covid-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze in depth the relationship of myeloid cell&#xD;
      subpopulations during infection by Severe acute respiratory syndrome coronavirus 2&#xD;
      (SARS-Cov2), the virus mediating Covid-19. Myeloid cells include neutrophils, monocytes and&#xD;
      dendritic cells, each divided into subpopulations with different functions in immune defense&#xD;
      and immune pathologies.&#xD;
&#xD;
      The study is based on the following hypotheses:&#xD;
&#xD;
        -  Infection and the interferon response to infection may induce hyperactive or&#xD;
           immunosuppressive differentiation of myeloid cells, that may be treated by specific&#xD;
           inhibitors.&#xD;
&#xD;
        -  Some myeloid cell subpopulations currently identified in our laboratories might be&#xD;
           markers for Covid-19 prognosis.&#xD;
&#xD;
        -  Alternative receptors may be present on myeloid cells, inducing the cytokine storm, a&#xD;
           target for therapy.&#xD;
&#xD;
        -  The expression of Interferon (IFN) receptor and IFN responding genes on myeloid cells&#xD;
           and on respiratory epithelial cells may correlate with prognosis and indicate potential&#xD;
           treatment targets.&#xD;
&#xD;
        -  Interferon responses are known to be skewed during Covid-19, but some IFN subtype&#xD;
           polymorphisms may correlate with prognosis and these subtypes migt be supplemented or&#xD;
           inhibited for therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infection by SARS-Cov2 drives to pneumonia in most cases, 30 percent of which require&#xD;
      hospitalization in a pneumology ward, among which 30 percent with severe acute respiratory&#xD;
      syndrome (SARS) must go to critical care units, with a high mortality rate.&#xD;
&#xD;
      This infection drives a strong cytokine response. In patients developing SARS, a profound,&#xD;
      paradoxical defect in IFN alpha and in the expression of genes responding to IFN alpha was&#xD;
      discovered. IFNs are strong anti-viral proteins, used for the treatment of viral hepatitis.&#xD;
      Type I IFNs, including IFN alpha, have ubiquitous receptors on almost every cell type. Type&#xD;
      III IFNs, or IFN lambda, have a more restricted receptor expression, including on&#xD;
      neutrophils. Their polymorphisms were already related to the prognosis of another ribonucleic&#xD;
      acid (RNA) virus with mucosal entry, hepatitis C virus (HCV), especially in people with&#xD;
      African origins.&#xD;
&#xD;
      Coronaviruses responsible for the previous SARS-Cov or Middle East respiratory syndrome&#xD;
      coronavirus (MERS-Cov) epidemics induce a defective IFN signal transduction. Many other viral&#xD;
      infection lead to desensitization. Moreover, IFN alpha by itself can lead to defective&#xD;
      antiviral responses. At the immune cell level, lymphopenia with an increased&#xD;
      neutrophil/lymphocyte ratio were noted in severe SARS-Cov2 case. New subpopulations of&#xD;
      neutrophils have been characterized by phenotypic and proteomic studies, with inflammatory or&#xD;
      suppressive functions.&#xD;
&#xD;
      It will be important to know if&#xD;
&#xD;
        -  hyperactive or immunosuppressive myeloid cell differentiation is caused by SARS-Cov2 and&#xD;
           can be inhibited specifically.&#xD;
&#xD;
        -  some myeloid subpopulations&#xD;
&#xD;
        -  correlate with the prognosis of the disease,&#xD;
&#xD;
        -  myeloid cells have alternative receptors for SARS-Cov2,&#xD;
&#xD;
        -  some IFN polymorphisms may correlate with prognosis and might be supplemented or&#xD;
           inhibited for therapy.&#xD;
&#xD;
      The answers will be obtained through the primary and secondary outcome measures, as described&#xD;
      below.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myeloid cell sub-population phenotype</measure>
    <time_frame>Month zero-month 36</time_frame>
    <description>Cytometric analysis of surface and intracellular molecules to identify myeloid cell sub-populations and define their function in vivo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myeloid cell functions</measure>
    <time_frame>Month zero-month 36</time_frame>
    <description>Cell culture and cytometric and analyte analysis of their functions, including IFN production</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myeloid cell transcriptomic and proteomic study</measure>
    <time_frame>Month zero-month 36</time_frame>
    <description>Transcriptomic and proteomic analysis of the functions of myeloid cell subtypes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomic study of nasal epithelial cells</measure>
    <time_frame>Month zero-month 36</time_frame>
    <description>Single cell RNA sequencing of the nasal brush products</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma analyte concentration measurement</measure>
    <time_frame>Month zero-month 36</time_frame>
    <description>High sensitivity detection by state-of-the art ELISA type methods</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Covid-19; SARS-Cov2</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Former mild SARS-Cov2 Pneumonia, 2 to 12 moths before, ≤ 5 L/mn Oxygen treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Former severe SARS-Cov2 Pneumonia, 2 to 12 moths before, &gt; 5 L/mn Oxygen treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Physician examination in the Pneumology ward, Cochin Hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Current hospitalization for Sars-Cov2 Pneumonia at Cochin Hospital</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Peripheral Blood sampling, 25 mL</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nasal Brushing</intervention_name>
    <description>Nasal Brushing, facultative</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Sex : male or female&#xD;
&#xD;
          -  French Social Security insurance&#xD;
&#xD;
          -  Information and consent dated and signed *&#xD;
&#xD;
          -  Group 1 : inclusion 2 to 12 months after hospitalization for Covid-19 pneumonia with&#xD;
             mild severity (oxygen treatment ≤5L/mn);&#xD;
&#xD;
          -  Group 2 : 2 to 12 months after hospitalization for Covid-19 pneumonia with high&#xD;
             severity (oxygen treatment &gt;5L/mn);&#xD;
&#xD;
          -  Group 3 : external visit at Cochin Hospital, age- and sex -matched with Groups 1, 2,&#xD;
             4.&#xD;
&#xD;
          -  Group 4 : inclusion during hospitalization for Covid-19, within the first month of&#xD;
             symptoms.&#xD;
&#xD;
               -  : If the clinical status of a patient from Group 4 does not allow immediate&#xD;
                  consent in ethically acceptable conditions, consent will be obtained from the&#xD;
                  patient's trusted person, or by default from a family member, if present. If not,&#xD;
                  the patient can still be included. He or she will be informed later an consent&#xD;
                  will be sought for potential pursuit of the research and for use of the data (law&#xD;
                  2004-806, August 09 2004-article L1122-1-2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tuberculosis or other evolutive bacterial infection&#xD;
&#xD;
          -  Chronic evolutive viral Infections (Hepatitis B or C, HIV)&#xD;
&#xD;
          -  Ongoing chemotherapy or radiotherapy&#xD;
&#xD;
          -  Participation in another research protocol with current exclusion period at the time&#xD;
             of pre-inclusion (possible inclusion in an observational study&#xD;
&#xD;
          -  Vulnerable person (pregnant, parturient woman, breastfeeding woman, person Under&#xD;
             tutorship, person under arrest through judiciary or administrative decision )&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Régis Burgel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cochin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre-Régis Burgel, MD, PhD</last_name>
    <phone>01 58 41 23 49</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre-regis.burgel@cch.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie BENHAMMANI-Godard</last_name>
    <phone>01 58 41 12 11</phone>
    <phone_ext>+33</phone_ext>
    <email>marie.godard@aphp.fr</email>
  </overall_contact_backup>
  <link>
    <url>https://www.institutcochin.fr/la-recherche/3i/equipe-hosmalin</url>
    <description>Team Hosmalin</description>
  </link>
  <link>
    <url>https://www.institutcochin.fr/la-recherche/3i/equipe-witko_sarsat</url>
    <description>Team Sarsat</description>
  </link>
  <link>
    <url>https://www.institutcochin.fr/la-recherche/3i/equipe-niedergang</url>
    <description>Team Niedergang</description>
  </link>
  <link>
    <url>https://www.institutcochin.fr/la-recherche/3i/equipe-chiche</url>
    <description>Team Chiche and Burgel</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>Neutrophils</keyword>
  <keyword>Dendritic cells</keyword>
  <keyword>Monocytes</keyword>
  <keyword>Macrophages</keyword>
  <keyword>Interferons</keyword>
  <keyword>Nasal mucosa</keyword>
  <keyword>Peripheral blood</keyword>
  <keyword>Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

